Team

Dr. Yasaman Kalantar-Motamedi — Founder, Chief Scientific Officer, computational biology.

Dr. Yasaman Kalantar-Motamedi brings scientific and operational judgment to Agemica's translational agenda, connecting research discipline with the practical requirements of therapeutic development.

Dr. Yasaman Kalantar-Motamedi
Founder, Chief Scientific OfficerCambridge · UCL
Bio

Dr. Yasaman Kalantar-Motamedi.

Computational biologist focused on AI drug discovery, multi-omics, and therapeutic prediction. PhD, Cambridge, focused on AI for drug discovery; MSc in Machine Learning from University College London. 12 years in AI for drug discovery and vaccine design. Leads the scientific architecture behind Agemica's AI discovery stack, connecting computational prediction with experimental validation.

PhD, Cambridge, focused on AI for drug discovery.

12 years of experience in AI for drug discovery and vaccine design.

MSc in Machine Learning from University College London.

UCL research roots in AI drug discovery and multi-omics integration.

Therapeutic prediction across cancer cell line panels.

Leads the scientific architecture behind Agemica's AI discovery stack, connecting computational prediction with experimental validation.

Architect of the AGEMICA Therapy Design AI subsystem.

Next · Team
Prof. Michael Snyder
Continue
Platform
Therapy Design AI
Continue